When this formula was applied to GBM patients without MGMT promoter methylation, there was no difference in survival time between high- and low-risk groups irrespective of whether the cutoff value was the same as the one used in the previous analyses or was the median risk score for this group of patients (Supplementary Figure S3A, B). The gene discussed is MGMT; the disease is glioblastoma.